Skip to content

Olema Pharmaceuticals, Inc. OLMA Secured lines of credit

Secured lines of credit at other companies

Arrowhead Research logo
Arrowhead ResearchARWR

Other financials

Income statement

See full
Operating income-$58.0M-66.3%
Net income-$53.1M-74.7%
EPS (diluted)-$0.52-44.4%

Balance sheet

See full
Cash & equivalents$52.5M+3.8%
Total debt$956.0K-16.7%
Total equity$480.5M+25.3%
Total assets$530.6M+29.5%

Cash flow

See full
Operating cash flow-$46.0M-4.6%
CapEx-
Free cash flow-$34.5M-27.8%

Valuation

See full
Market cap$998.38M+253%
Enterprise value$946.79M+306%

Returns & leverage

See full
Return on equity-42.9%+1.3pp
Debt / equity0.0×
Current ratio10.9×-4.3×

Where this comes from

Reported directly by Olema Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LongTermLineOfCredit.

The official record: Olema Pharmaceuticals, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Olema Pharmaceuticals, Inc.'s secured lines of credit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Olema Pharmaceuticals, Inc.'s secured lines of credit?
Olema Pharmaceuticals, Inc. (OLMA) reported secured lines of credit of $3M in Q1 2026.